Nanomaterial Technology and Soft Tissue Sarcomas

Changkai Zhou; Xue Chen; Ying Huang; Qi Zhang; Shu Zhu; Wei Fu

doi:10.3389/fonc.2022.921983

Nanomaterial Technology and Soft Tissue Sarcomas

Front Oncol. 2022 Jun 22:12:921983. doi: 10.3389/fonc.2022.921983. eCollection 2022.

Authors

Changkai Zhou¹, Xue Chen², Ying Huang³, Qi Zhang², Shu Zhu⁴, Wei Fu⁵

Affiliations

¹ Department of Burn and Plastic Surgery, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital, Nantong, China.
² Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³ Department of Operation Room, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital, Nantong, China.
⁴ Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
⁵ Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract

Soft tissue sarcomas (STSs) are relatively rare heterogeneous solid tumors of the mesenchymal origin. They account for approximately 1% of all malignant tumors in adults and have more than 70 histological subtypes. Consequently, the rarity and heterogeneity of STSs make their diagnosis and treatment very challenging. Nanotechnology has attracted increasing attention from researchers due to the unique physicochemical and biological properties of nanomaterials with potential medical applications as nanoprobes, drug delivery systems, photosensitizers, radioenhancers, antitumor agents, and their combinations for cancer diagnosis and treatment. This review discusses the progress made in the use of nanotechnology for the diagnosis and treatment of STSs and highlights future prospects of the STS multimodality therapy.

Keywords: cancer diagnosis; drug delivery; nanotechnology; photodynamic therapy; radiotherapy; soft tissue sarcoma.

Publication types

Review